Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.51
  • Today's Change-0.021 / -0.59%
  • Shares traded1.66k
  • 1 Year change-16.45%
  • Beta0.1137
Data delayed at least 15 minutes, as of Feb 12 2026 15:21 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

  • Revenue in USD (TTM)318.03k
  • Net income in USD-8.66m
  • Incorporated1997
  • Employees9.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shanrong Biotechnology Corp1.32m-5.08m60.02m3.00------45.31-15.40-15.404.10-11.404.45--11.81441,576.70-1,705.30-----------383.32--0.0315-16.22----91.44---86.62------
Annovis Bio Inc0.00-24.88m62.81m8.00--3.64-----1.41-1.410.000.65170.00----0.00-157.74-116.87-221.93-138.75------------0.00------56.25------
Adicet Bio Inc0.00-115.01m65.23m152.00--0.3247-----20.22-20.220.0020.980.00----0.00-59.52-36.24-66.08-39.41-------813.80----0.0088------17.90--32.77--
Maia Biotechnology Inc0.00-22.34m65.55m13.00--1,463.37-----0.7504-0.75040.000.00120.00----0.00-212.50-208.29-602.02-373.18------------0.00-------17.61------
Fractyl Health Inc3.00k-122.20m66.43m107.00------22,141.81-2.27-2.270.00006-0.0240.00002----28.04-101.33-78.52-118.18-97.44100.00---4,073,233.00-122,747.90---31.401.12---22.50--25.29--78.65--
Gain Therapeutics Inc0.00-19.39m66.92m23.00--10.59-----0.6364-0.63640.000.16430.00----0.00-153.07-79.58-234.03-95.32-------19,975.78---33.790.067---100.00--8.34--10.39--
Coeptis Therapeutics Holdings Inc500.99k-11.28m69.09m5.00--5.97--137.91-3.47-3.470.14762.010.0433--11.65100,198.00-118.13-42.24-167.86-44.3272.96---2,727.81-----73.660.0224------53.85------
Alterity Therapeutics Ltd (ADR)318.03k-8.66m69.24m9.00--1.78--217.72-0.8765-0.87650.02981.990.0137--5,578.6335,336.30-37.23-49.00-43.12-57.35-----2,721.96-9,708.51---211.820.0037--66.2791.9736.48------
XBiotech Inc0.00-29.16m72.26m88.00--0.4325-----0.9566-0.95660.005.480.00----0.00-15.25-7.74-16.08-8.02-------187.68----0.00-------56.90--44.92--
Nuo Therapeutics Inc2.61m-2.43m72.42m--------27.73-0.0517-0.05170.0555-0.00881.434.195.32---133.29-121.45-289.99-243.0570.3878.52-93.06-424.191.00-17,110.33----124.3456.3426.73------
Ibio Inc500.00k-20.11m76.34m20.00--0.7988--152.68-1.44-1.440.02322.770.0113--15.3825,000.00-45.35-30.90-50.81-37.76-----4,021.60-2,374.12----0.0127--77.78-24.57-19.00---57.50--
Medicinova Inc257.92k-12.01m78.14m13.00--1.77--302.97-0.2449-0.24490.00530.89640.0049----19,840.00-22.73-15.56-24.08-16.17-----4,656.61-1,144.98----0.00---100.00---28.91---39.68--
TuHURA Biosciences Inc0.00-43.77m78.33m19.00--4.01-----1.60-1.600.000.32730.00----0.00-286.97---456.76-------------9.010.0286--------------
ImageneBio Inc0.00-46.14m78.50m15.00--0.5614-----8.11-8.110.0012.510.00----0.00-29.23-29.58-31.29-33.67-------407.25----0.00---100.00--27.77------
Data as of Feb 12 2026. Currency figures normalised to Alterity Therapeutics Ltd's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.